Market Overview

Pfizer Says Xalkori Gets Conditional OK to Treat in EU

Related PFE
Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Reckitt Benckiser backs away from Pfizer's consumer healthcare unit (Seeking Alpha)

Pfizer Inc. announced today that the European Commission has given conditional marketing authorization for XALKORI^® (crizotinib) in the European Union (EU) for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

“In the field of metastatic non-small cell lung cancer, XALKORI represents a major advancement. It brings to the patients with ALK-translocated tumors an oral compound that can achieve tumor shrinkage and delay disease progression,” said Dr. Jean-Charles Soria, professor of Medicine and Medical Oncology at South-Paris University and cancer specialist at Institut Gustave Roussy, France.

Posted-In: News FDA


Related Articles (PFE)

View Comments and Join the Discussion!